Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   36828   clinical trials with a EudraCT protocol, of which   6080   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2006-006677-25
    Sponsor's Protocol Code Number:LTE6672
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2007-06-22
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2006-006677-25
    A.3Full title of the trial
    Efficacy and safety of 2mg/day of M100907 on Sleep Maintenance Insomnia with a sub-study of the effect of M100907 on stable Type II Diabetes Mellitus: a 12-week, multi-center, randomized, double-blind, placebo-controlled study
    A.3.2Name or abbreviated title of the trial where available
    SAMS 12 (Sleep And Metabolism Study, 12 weeks)
    A.4.1Sponsor's protocol code numberLTE6672
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of Sponsorsanofi-aventis recherche & développement
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameVolinanserin
    D.3.2Product code M100907
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNvolinanserin
    D.3.9.1CAS number 139290-65-6
    D.3.9.2Current sponsor codeM100907
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product Information not present in EudraCT
    D. ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D. on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Sleep maintenance insomnia (+ subpopulation of stable type II Diabetes Mellitus)
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    •To demonstrate efficacy of M100907 2 mg/day in comparison to placebo for Sleep Maintenance Insomnia using change from baseline to 12 weeks of patient reported Wake After Sleep Onset (pr-WASO).
    E.2.2Secondary objectives of the trial
    *Key Secondary:
    •To demonstrate efficacy of M100907 in comparison to placebo in improving patient’s daytime functioning using change from baseline to 12 weeks in the “General Productivity” Domain score of the Functional Outcomes of Sleep Questionnaire (FOSQ).
    *Other Secondary Objectives:
    •Sleep: to assess efficacy of M100907 2 mg/d in comparison to placebo as change from baseline to 12 weeks on other parameters of patient’s sleep questionnaire.
    •To assess clinical safety and tolerability of M100907 2 mg/day in comparison to placebo during the 12 weeks of treatment
    •To evaluate subjective next morning residual effects associated with M100907 2 mg/day as compared to placebo at 12 weeks of treatment
    •To assess during the one-week run-out period the effect on sleep (pr-WASO, pr-TST), following abrupt discontinuation after 12 weeks of study treatment with M100907 2mg/day in comparison to placebo
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Sub-population of type II diabetes mellitus with SMI: The objectives in this sub-study will be:
    To demonstrate improved glycemic control in patients with type II diabetes mellitus and sleep maintenance insomnia using change from baseline of HbA1C at 12 weeks.
    To evaluate efficacy through reduction in dose of medicine(s) required for adequate diabetes control after 12 weeks of treatment with M100907.
    To demonstrate improved glycemic control in patients with type II diabetes mellitus and sleep maintenance insomnia using change from baseline of fructosamine at 12 weeks.
    •Safety in type II Diabetes Mellitus
    To establish the safety and tolerability of M100907 2 mg/d in patients with type II Diabetes Mellitus
    E.3Principal inclusion criteria
    *Related to patients:
    -Out-patients ≥ 18 years of age or the legal age of consent in the area where the study is being done.
    -Woman of childbearing potential (less than two years post-menopausal or not surgically sterile), must have a negative urine pregnancy test at screening – and must use a highly effective method of birth control for at least one month prior to screening, which is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, IUDs containing hormones, sexual abstinence (unless not acceptable by the local health authorities) or vasectomised partner.
    *Related to sleep disorders:
    -Each patient must have primary insomnia based on criteria (DSM IV-TR) with predominant complaints of difficulty in maintaining sleep (nocturnal awakenings or early morning awakenings), for at least one month preceding the study visit, and having clinically significant distress or impairment in social occupational or other important areas of functioning.
    -Based on patient’s information, the patient must complain of at least one hour of wakefulness after sleep onset for at least 4 or more nights per week over the preceding month.
    -Based on patient’s information, the patient has spent at least 6.5 hours and not more than 9.0 hours, in bed, each night, over the preceding two weeks.
    -Patient must report impact daytime functioning associated with sleep maintenance insomnia as measured by question 3 of Insomnia Severity Index at screening and randomization visits. To be included patient’s answer should be either: 2 (= Somewhat interfering), or 3 (= Much), or 4 (= Very Much Interfering) at both visits.
    -Based on the information recorded in the patient’s sleep questionnaire during the screening week preceding the randomization the following criteria must be present:
    • In the Screening Period (5 –10 days) more than a half (>50%) of nights must have WASO ≥ 60 min.
    • TST ≤ 7 hours and ≥ 3 hours on 3-worst screening nights.
    • Excluding one night in the Screening Period (5 – 10 days) with the highest Sleep Onset Latency (SOL) value, the mean SOL for the Screening Period must be ≤ 30 min.
    *Related to Type II Diabetes Mellitus
    -Patients with type II diabetes (WHO definition) must have been on an oral hypoglycemic agent(s) and/or insulin for at least 3 months prior to the Screening Visit (stable regimen for at least one month prior to Screening Visit).
    E.4Principal exclusion criteria
    *Related to patients:
    -Females who are lactating or who are pregnant.
    -Night shift workers, and individuals who nap 3 or more times per week over the preceding month.
    -Consumption of xanthine-containing beverages (i.e. tea, coffee, or cola) comprising usually more than 5 cups or glasses per day.
    -Participation in another trial having received study medication within one month before the screening visit.
    -Body mass index ≥ 33 calculated from patient’s height (m) and weight (kg); weight (kg)/height (m²).
    -Use of any over-the-counter including tryptophan, valerian root (Valeriana officinalis), kava (Piper methysticum Forst), melatonin, St. John’s Wort (Hypericum perforatum), Alluna (herbal supplement with valerian root) or prescription sleep medication, including hypnotics and sedatives, and anxiolytics, within one week or five half-lives (whichever is longer), prior to screening.
    -Use of any substance with psychotropic effects or properties known to affect sleep/wake, including, but not limited to: neuroleptics, morphine/opioid derivatives, sedative antihistamines, stimulants, antidepressants, clonidine, within one week or five half-lives (whichever is longer), prior to screening.
    -Patients unable to complete the study questionnaires.
    -Patients unwilling to provide written, signed and dated informed consent must not be included in the study.
    -Patients who are unable to participate for the entire duration of the study, or in the opinion of the investigator, are likely to be non-compliant with the obligations inherent in the trial participation.
    *Related to sleep disorders:
    -History of (i) primary hypersomnia, (ii) narcolepsy, (iii) breathing-related sleep disorder, (iv) circadian rhythm sleep disorder, (v) parasomnia (e.g. somnambulism), (vi) dyssomnia not otherwise specified, i.e., periodic leg movement syndrome.
    *Related to concomitant illnesses:
    -Patients presenting with acute or chronic pain resulting in insomnia.
    -Patients with current psychiatric disturbances according to DSM IV criteria including but not limited to psychosis and/or bipolar disorder, obsessive compulsive disorder, major depression, anxiety disorders, panic disorders, eating disorder, alcohol or substance abuse or dependence -except nicotine-, or a history of lifetime psychosis and/or bipolar disorder.
    -Patients with mental retardation or dementia.
    -Patients with a history of epilepsy or seizures (not including benign neonatal and childhood convulsions).
    -Evidence of any clinically significant, severe or unstable, acute or chronically progressive medical or surgical disorder, or any condition that may interfere with the absorption, metabolism, distribution or excretion of the study drug, or may affect patient safety.
    -Clinically significant and abnormal ECG (including QTcF ≥ 500ms).
    -Serious head injury or stroke within the past year.
    -Positive qualitative urine drug screen (opiates, cocaine, amphetamine, cannabinoids, barbiturates, phencyclidine, benzodiazepines, methadone, propoxyphene) at screening.
    *Related to Diabetes Mellitus Type II
    -HbA1C level of ≥ 9.5% at the Screening Visit.
    -HbA1C level of < or = to 6.5% at the Screening Visit. (Note: diabetic patients with HbA1C level of < or = to 6.5% may be included in the main study population).
    -Fasting Plasma Glucose ≥ 250 mg/dL (14.0 mmol/L) at the Screening Visit.
    -Patients with poorly controlled diabetes; i.e., a history of hospitalization for ketoacidosis within the past 12 months.
    E.5 End points
    E.5.1Primary end point(s)
    •Primary Endpoint: Change from baseline to 12-week of the mean patient reported WASO derived from patient’s sleep questionnaire.
    •Key secondary endpoint: Change from baseline to 12-week of “General Productivity” domain from Functional Outcomes of Sleep Questionnaire (FOSQ).
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans Information not present in EudraCT
    E.7.1.2Bioequivalence study Information not present in EudraCT
    E.7.1.3Other Information not present in EudraCT
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned Information not present in EudraCT
    E.8.4 The trial involves multiple sites in the Member State concerned Information not present in EudraCT
    E.8.4.1Number of sites anticipated in Member State concerned9
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA33
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Information not present in EudraCT
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 195
    F.4.2.2In the whole clinical trial 840
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2007-07-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2007-10-09
    P. End of Trial
    P.End of Trial StatusOngoing
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice